About the Institute

In 2003 the INR published the first of its many peer-reviewed scientific publications documenting the INR's medical breakthroughs in the field of neuroinflammation. Since that time scientists around the world have developed supporting evidence that suggests, in accordance with the findings of INR physicians, that dormant circuits in the brain and other parts of the central nervous system, following stroke and other forms of injury, are capable of being re-activated, resulting in rapid neurological improvement. The INR's breakthrough treatment is not experimental: it has been used for thousands of patients from every populated continent in the world.

Hundreds of scientific articles from academic scientists have cited INR publications. In addition to patient care, the INR trains physicians in the proper implementation of its patented, off-label treatment methods. The INR Physician Training Program has been attended by physicians from six continents.

The INR's issued and pending U.S. and foreign patents, include, but are not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8,900,583; Australian patents 758523 and 2011323616 B2, Canadian patent 2,811,948, European patent ES2620749 (T3), etc., all assigned to TACT IP LLC.